Viking Therapeutics, Inc. Email Format

Pharmaceutical ManufacturingCalifornia, United States51-200 Employees

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders. Based in San Diego, California, it advances a portfolio of first-in-class or best-in-class programs targeting metabolic pathways. Its lead programs include VK2735, a dual GLP-1 and GIP receptor agonist for obesity in Phase 3 trials, with both injectable and oral formulations under assessment, and VK2809, a thyroid hormone receptor beta agonist studied for non-alcoholic steatohepatitis (NASH) with fibrosis endpoints, as well as non-alcoholic fatty liver disease and associated LDL-C reductions. The company is also pursuing a line of DACRAs for obesity and related metabolic disorders and VK0214 for X-linked adrenoleukodystrophy, a rare disease program. Recent developments include efforts to broaden delivery options for its weight-loss candidate, including a pill and injectable form, reflecting ongoing clinical expansion.

Get verified Viking Therapeutics, Inc. emails free

Company overview Employee directory